ESMO 2022 Kidney Cancer

Viewing 1-18 of 18 articles

ESMO 2022: Invited Discussant: Results of COSMIC-313

ESMO 2022: Multidisciplinary Updates in Biomarkers in Urinary Cancers: The Microbiome

ESMO 2022: Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma of IMDC Intermediate or Poor Risk (COSMIC-313)

ESMO 2022: Invited Discussant: BIONIKK trial, Changes in Gut Microbiota, & LITESPARK-004 trial

ESMO 2022: Invited Discussant: Results of the Phase 2 LITESPARK-003 Trial

ESMO 2022: Longitudinal Analysis Reveals Gut Microbiota Shift During Standard Therapies in Metastatic Renal Cell Carcinoma (mRCC)

ESMO 2022: Invited Discussant: The Results of the PIVOT-09 Trial & the Role of Enfortumab Vedotin

ESMO 2022: Phase 2 Study of Belzutifan plus Cabozantinib as First-Line Treatment of Advanced Renal Cell Carcinoma Cohort 1 of LITESPARK-003

ESMO 2022: Bempegaldesleukin plus Nivolumab Compared to the Investigator’s Choice of Sunitinib or Cabozantinib in Previously Untreated Advanced Renal Cell Carcinoma Results from a Phase 3 Randomized Study

ESMO 2022: In-Situ Immune Markers Predict Nivolumab (N) +/-Ipilimumab (I) Efficacy in Frontline Metastatic Clear Cell Renal Cell Carcinoma (mccRCC): Key Ancillary Analyses from the BIONIKK Randomized Trial

ESMO 2022: Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) Disease–Associated Neoplasms: 36 Months of Follow-Up of the Phase 2 LITESPARK-004 Study

ESMO 2022: Updated Results From the CLEAR Trial and the Final Results of TITAN-RCC Discussion

ESMO 2022: Efficacy of a Tailored Approach With Nivolumab and Nivolumab/ipilimumab as Immunotherapeutic Boost in Metastatic Renal Cell Carcinoma – Final Results of TITAN-RCC

ESMO 2022: Updated Efficacy of Lenvatinib + Pembrolizumab Vs Sunitinib in Patients With Advanced Renal Cell Carcinoma in the CLEAR Study

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial

ESMO 2022: Do the Results of the Perioperative Renal Cancer Trials Make Any Sense?

ESMO 2022: IMmotion010: Efficacy and Safety from the Phase III Study of Atezolizumab vs Placebo as Adjuvant Therapy in Patients with RCC at Increased Risk of Recurrence After Resection

ESMO 2022: Phase III RandOmized Study Comparing PErioperative Nivolumab versus Observation in Patients with RCC Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network Trial